Results 221 to 230 of about 612,123 (266)
FEBS Open Bio, EarlyView.Activation of the mitochondrial protein OXR1 increases pSyn129 αSynuclein aggregation by lowering ATP levels and altering mitochondrial membrane potential, particularly in response to MSA‐derived fibrils. In contrast, ablation of the ER protein EMC4 enhances autophagic flux and lysosomal clearance, broadly reducing α‐synuclein aggregates.
Sandesh Neupane +11 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Molecular targets in cancer therapy
Expert Review of Anticancer Therapy, 201324th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics' 6-9 November 2012, Dublin, Ireland The EORTC-NCI-AACR Symposium is an annual meeting, jointly hosted by the European Organization for Research and Treatment of Cancer, the US National Cancer Institute and the American Association for Cancer Research, to encourage exchange of ...
Shivaani, Kummar, James H, Doroshow
openaire +2 more sources
Molecular targets of gene therapy
The Annals of Thoracic Surgery, 1999Ischemic reperfused heart represents a potential target for gene therapy because gene transfer can represent an alternate pharmacological approach to protect the heart from cellular injury. Gene therapy may be particularly useful to deal with previously unapproachable problems.
D K, Das +5 more
openaire +2 more sources
Molecular Targets for Papillomavirus Therapy
Current Drug Target -Infectious Disorders, 2003Papillomaviruses are infectious agents for human and animal epithelial tissue, and nearly 100 distinct human types (HPVs) have been identified. When these viruses infect cutaneous or mucosal skin they can initially cause clinical warts or persistent infection with little or no visible manifestations.
V G, Wilson, G, Rosas-Acosta
openaire +2 more sources
Molecular Targeting of Lymphatics for Therapy
Current Pharmaceutical Design, 2004The dysfunction or proliferation of lymphatic vessels (lymphangiogenesis) is linked to a number of pathological conditions including lymphedema and cancer. The recent discovery and characterisation of the lymphangiogenic growth factors vascular endothelial growth factor-C (VEGF-C) and VEGF-D and of their receptor on lymphatic endothelial cells, VEGFR-3,
S A, Stacker, R A, Hughes, M G, Achen
openaire +2 more sources
Targeted Molecular Therapy in Melanoma
Seminars in Cutaneous Medicine and Surgery, 2010Immunotherapy and chemotherapy benefit few patients with metastatic melanoma, and even fewer experience durable survival benefit. These poor results may come from treating all melanomas as though they are biologically homogeneous. Recently, it has been shown that targeting specific activated tyrosine kinases (oncogenes) can have striking clinical ...
Igor, Puzanov, Keith T, Flaherty
openaire +2 more sources
Molecular Targets of Antiviral Therapy
New England Journal of Medicine, 1989THE development of specific antiviral drugs that are minimally toxic to normal cells has ushered in a new era of antiviral therapy.
Jeffrey S. Flier +2 more
openaire +2 more sources
Molecular Targets and Targeted Therapies for Malignant Mesothelioma
Current Medicinal Chemistry, 2008Malignant mesothelioma is a highly invasive tumor originating from the mesothelial linings of the pleura, peritoneum and pericardium. It is seldom amenable to surgical intervention and poorly responsive to radiotherapy, leaving chemotherapy as the main therapeutic option for most patients. The development of effective drug regimens against mesothelioma
PALUMBO, CAMILLA +3 more
openaire +3 more sources
Molecular targets in cancer therapy
Seminars in Oncology Nursing, 2003To review selected pharmacologic agents that target key cellular processes along with their mechanisms of action and adverse events. Nursing implications including what patients and families need to know, administration issues, and management of common toxicities will be reviewed.Research articles, clinical trials, abstracts, and book chapters ...
openaire +2 more sources
2019
The treatment of advanced thyroid cancer has developed with increased understanding of the molecular basis of the disease. Alongside this targeted therapies have been developed, and there is evidence of efficacy for multikinase inhibitors in improving progression-free survival in this population of patients.
Arabella Hunt, Kate L. Newbold
openaire +1 more source
The treatment of advanced thyroid cancer has developed with increased understanding of the molecular basis of the disease. Alongside this targeted therapies have been developed, and there is evidence of efficacy for multikinase inhibitors in improving progression-free survival in this population of patients.
Arabella Hunt, Kate L. Newbold
openaire +1 more source